XTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose

Similar documents
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338

Arena Pharmaceuticals, Inc., Department of Drug Metabolism and Pharmacokinetics, San Diego, California

CYTOCHROME P450: Structure-Function

High-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage

In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases

Strategies for In Vitro Metabolic Stability Testing. Christopher Patten, PhD. BD Biosciences December 2, 2009

Pilot experiments to investigate the glucuronidation of axitinib with human liver microsomes.

An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes

MEDCH/PCEUT 527 ADVANCED DRUG METABOLISM 2019 Course Coordinators: Allan Rettie and Ken Thummel When/ Where:

PREDICTING PHARMACOKINETICS FOLLOWING TOPICAL APPLICATION USING NON-ANIMAL METHODS IAN SORRELL, MI-YOUNG LEE, RICHARD CUBBERLEY

Chapter 4. Drug Biotransformation

Supplemental material to this article can be found at:

The metabolism of 1 - and 4-hydroxymidazolam by glucuronide conjugation is. largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7

ANTHONY J. LEE, JOSEPH W. KOSH, ALLAN H. CONNEY, 1 and BAO TING ZHU. ABSTRACT We characterized the NADPH-dependent metabolism of 17 estradiol

Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and

Effect of BD Matrigel Matrix Overlay and BD Matrigel Matrix Thin Coat on CYP450 Activities in Cryo Human Hepatocytes. Rongjun Zuo.

Chris Bohl, Ph.D. Global Technical Support Manager- Products

Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes

Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters

Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu

Metabolism of 1 - and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7

Carolina Säll, J. Brian Houston, and Aleksandra Galetin

In vitro assay of six UGT isoforms in human liver microsomes, using cocktails of probe substrates and LC-MS/MS

Corydaline Inhibits Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes

Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney

Received: 2 August 2017; Accepted: 13 September 2017; Published: 21 September 2017

Michelle Schaefer, Gerhard Schänzle, Daniel Bischoff, and Roderich D. Süssmuth.

XenoTech LLC, Lenexa, KS, USA. Full text of this paper is available at

Supplemental material to this article can be found at:

Discovery of a highly selective CYP3A4 inhibitor suitable for reaction. phenotyping studies and differentiation of CYP3A4 and CYP3A5

Pharmacokinetics and Metabolism (Toxicokinetics)

Cryo Characterization Report (CCR)

Objectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy

Cover Page. The handle holds various files of this Leiden University dissertation

Enhanced method development workflow for modern LC and SFC

Cryopreserved Enterocytes for the Evaluation of Drug-Drug and Food- Drug Interactions

Sylvie Klieber, Catherine Arabeyre-Fabre, Patricia Moliner, Eric Marti, Martine Mandray, Robert Ngo, Celine Ollier, Priscilla Brun & Gerard Fabre

EFFECT OF OBESITY ON HEPATIC DRUG METABOLISM A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY

Constitutive Regulation of P450s by Endocrine Factors

Novel Human-Based In Vitro Liver and Intestinal Technologies for Drug Development

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu , Republic of Korea 3

CYTOCHROME P-450 3A4 AND 2C8 ARE INVOLVED IN ZOPICLONE METABOLISM

Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B

Influence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments

Receiving Cryopreserved Human Hepatocytes

Inhibitory Effects of Garcinia cambogia Extract on CYP2B6 Enzyme Activity

British Journal of Clinical Pharmacology

Title Page. CYP-mediated sulfoximine de-imination of AZD6738. Authors: Barry C Jones, Roshini Markandu, Chungang Gu and Graeme Scarfe.

Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 49-OH-bupropion in vitro

This item is the archived peer-reviewed author-version of:

Muhammad Fawad Rasool Feras Khalil Stephanie Läer

CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: Interindividual differences in these contributions

Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions

Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine S

COPYRIGHTED MATERIAL IN VITRO EVALUATION OF METABOLIC DRUG DRUG INTERACTIONS: CONCEPTS AND PRACTICE ALBERT P. LI

METABOLISM OF ( )- AND ( )-LIMONENES TO RESPECTIVE CARVEOLS AND PERILLYL ALCOHOLS BY CYP2C9 AND CYP2C19 IN HUMAN LIVER MICROSOMES

DMD# human UDP-glucuronosyltransferases, species differences, and interaction potential

Cryopreserved Human Hepatocytes (Cat # HP-F)

In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters s

An Evaluation of the CYP450 Inhibition Potential of Lisdexamfetamine in. Human Liver Microsomes

Optimization of Experimental Conditions of Automated Glucuronidation Assays in

THE EFFECT OF INCUBATION CONDITIONS ON THE ENZYME KINETICS OF UDP-GLUCURONOSYLTRANSFERASES

Glucuronidation Converts Gemfibrozil to a Potent, Metabolism-Dependent. Inhibitor of CYP2C8: Implications for Drug-Drug Interactions

INVOLVEMENT OF CYP2E1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES

Received December 14, 2009; accepted March 19, 2010

Valproate Case 1: Pharmacokinetics Jose de Leon, MD

BIOMARKERS AND TOXICITY MECHANISMS 07 Mechanisms Metabolism & Detoxification. Luděk Bláha, PřF MU, RECETOX

Probe substrate and enzyme source-dependent inhibition of UDPglucuronosyltransferase

Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity

Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome

Effects of Liver Disease on Pharmacokinetics

Drug Metabolizing Enzymes and Reaction-Phenotyping

TECHNICAL BULLETIN. Primary Human Hepatocytes LifeNet Health

Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW

Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals

IN VITRO IDENTIFICATION OF THE HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF R( )- AND S( )-CARVEDILOL

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic

Months Years. Centimeters Inches Missing Reason: Not Done Unknown. Kilograms Pounds Missing Reason: Not Done Unknown. Female Male Unknown

Metabolic Profile, Enzyme Kinetics, and Reaction Phenotyping of β Lapachone Metabolism in Human Liver and Intestine in Vitro

AND LIVER MICROSOMAL P-450 PROFILES

Octanol / Water Partitioning Coefficient logp and ClogP

CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES

Characterization of human cytochrome P-450 enzymes involved in the metabolism of. the piperidine-type phenothiazine neuroleptic thioridazine

Evaluation of Cryopreserved Human Hepatocytes as an Alternative In Vitro System to

Metabolism Studies of Desvenlafaxine

Joan Eilstein. Metabolizing Enzymes in Human Skin. from SkinEthic TM. ADMET - Metabolism. L OREAL Advanced Research

METABOLISM OF MK-0524, A DP1 ANTAGONIST, IN MICROSOMES AND HEPATOCYTES FROM PRECLINICAL SPECIES AND HUMANS

Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?

Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data

Andrew Rowland, Kathleen M. Knights, Peter I. Mackenzie, and John O. Miners

Keywords ethinyl estradiol/norethindrone, isavuconazole, ketoconazole, midazolam, rifampin

Drug Interactions, from bench to bedside

Research Article Selective Inhibition of Bakuchicin Isolated from Psoralea corylifolia on CYP1A in Human Liver Microsomes

Novel Hepatocyte Technologies for the Evaluation of Adverse Drug Properties

Pediatric Drug Development Current Challenges

Characterization of the In Vitro and In Vivo Metabolism and Disposition and P450. Inhibition/Induction Profile of Saxagliptin in Human

Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies

Drug Metabolism Letters

Supplemental Information

Transcription:

XTreme 200 Human Liver Microsomes Lot No. 1710084 Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H2610 0.5 ml at 20 mg/ml H2620 1.0 ml at 20 mg/ml H2630 5.0 ml at 20 mg/ml H2640 50.0 ml at 20 mg/ml Specific Content and Enzyme Activities Content / Rate Cytochrome P450 content (nmol/mg protein) 0.335 Cytochrome b5 content (nmol/mg protein) 0.389 NADPH-cytochrome c reductase (nmol/mg protein/min) 214 ± 2 Enzyme Marker Substrate Reaction [S] (µm) Rate (pmol/mg protein/min) CYP1A2 Phenacetin O-dealkylation 80 530 ± 14 CYP2A6 Coumarin 7-hydroxylation 50 1650 ± 120 CYP2B6 Bupropion hydroxylation 500 673 ± 29 CYP2C8 Amodiaquine N-dealkylation 20 2080 ± 90 CYP2C9 Diclofenac 4'-hydroxylation 100 2100 ± 50 CYP2C19 S-Mephenytoin 4'-hydroxylation 400 89.3 ± 3.5 CYP2D6 Dextromethorphan O-demethylation 80 229 ± 11 CYP2E1 Chlorzoxazone 6-hydroxylation 500 1280 ± 80 CYP2J2 Ebastine hydroxylation 30 390 ± 8 CYP3A4/5 Testosterone 6β-hydroxylation 250 2940 ± 440 CYP3A4/5 Midazolam 1'-hydroxylation 30 822 ± 26 CYP4A11 Lauric acid 12-hydroxylation 100 1690 ± 50 FMO Benzydamine N-oxygenation 500 846 ± 29 UGT1A1 17β-Estradiol 3-glucuronidation 100 1770 ± 10 UGT1A3 Chenodeoxycholic acid 24O-glucuronidation 300 75.6 ± 2.4 UGT1A4 Trifluoperazine glucuronidation 25 650 ± 10 UGT1A6 1-Naphthol glucuronidation 1000 21390 ± 380 UGT1A9 Propofol glucuronidation 50 3500 ± 90 UGT2B7 Morphine 3-glucuronidation 1000 2700 ± 270 UGT2B17 17βO-Testosterone glucuronidation 200 662 ± 86 Characterization is performed when the first lot of a product from a given subcellular fraction (e.g., S9) is prepared. Subsequent lots are subject to a verification test only. Values for enzyme activities were determined at a single substrate concentration and are mean + standard deviation of three or more determinations. To measure cytochrome P450 (CYP) activity, liver microsomes (50 µg/ml) were incubated in triplicate at 37 ± 1 C for 10 minutes in potassium phosphate buffer (50 mm, ph 7.4), containing MgCl2 (3.0 mm), EDTA (1.0 mm), NADP (1.0 mm), glucose-6-phosphate (5.0 mm), glucose-6-phosphate dehydrogenase (1 Unit/mL) and marker substrate, at the final concentrations indicated. Metabolite formation was determined by validated LC-MS/MS methods with deuterated metabolites as internal standards. FMO activity was measured under similar conditions except the protein concentration was 1 mg/ml and the buffer was 49 mm Tricine (ph 8.5) To measure UDP-glucuronosyltransferase (UGT) activity, liver microsomes (10-250 µg/ml) were incubated in triplicate at 37 ± 1 C for 5 or 10 minutes in Tris-HCl (100 mm, ph 7.7 at 37 C), CHAPS (0.5 mm), EDTA (1.0 mm), MgCl2 (10 mm), D-saccharic acid 1,4-lactone (100 µm), uridine diphosphate-glucuronic acid (8.0 mm) and marker substrate at the final concentrations indicated. Each donor is equally represented in this pool. Store at -80 C CAUTION: This sample should be considered as a potential biohazard and universal precautions should be followed. Intended for in vitro use only. Datasheet prepared 19 December 2018

Kinetic constants for CYP enzyme activities in human liver microsomes (pool of 200) Enzyme Marker Substrate Kinetic Constants CL int: Intrinsic clearance (i.e., Vmax/Km). Km (µm) Kinetic constants are mean + standard deviation of three or more determinations. Vmax (pmol/mg protein/min) CL int (µl/mg protein/min) CYP1A2 Phenacetin 61.2 ± 3.0 1010 ± 20 16.5 [S] range: 12-120 µm CYP2A6 Coumarin 0.514 ± 0.027 770 ± 15 1498 [S] range: 0.15-7.5 µm CYP2B6 Bupropion 113 ± 8 695 ± 23 6.15 [S] range: 10-500 µm CYP2B6 Efavirenz 5.10 ± 0.29 133 ± 3 26.1 [S] range: 0.3-18 µm CYP2C8 Amodiaquine 2.50 ± 0.27 3020 ± 120 1208 (low protein concentration) [S] range: 0.05-18 µm CYP2C9 Diclofenac 8.45 ± 0.20 2960 ± 30 350 [S] range: 1.5-60 µm CYP2C19 S-Mephenytoin 69.6 ± 3.3 96.8 ± 2.1 1.39 [S] range: 8-400 µm CYP2D6 Dextromethorphan 9.07 ± 2.23 241 ± 25 26.6 [S] range: 1.5-75 µm CYP2E1 Chlorzoxazone 61.2 ± 2.8 2880 ± 60 47.1 [S] range: 4-300 µm CYP3A4/5 Testosterone 76.5 ± 4.5 6630 ± 170 86.7 [S] range: 20-210 µm CYP3A4/5 Midazolam 2.86 ± 0.26 1420 ± 40 497 [S] range: 1-40 µm CYP4A11 Lauric acid 1.35 ± 0.21 990 ± 61 733 [S] range: 0.3-15 µm Page 2 of 7

248 M 29 Hispanic Head trauma 255 M 46 Hispanic Anoxia 262 M 42 Caucasian Cerebrovascular accident 310 F 52 Caucasian Cerebrovascular accident 342 F 31 Caucasian Anoxia 375 M 23 Caucasian Head trauma 380 M 47 Caucasian Head trauma 384 M 53 Caucasian Anoxia 386 M 32 Caucasian Head trauma 400 F 42 Caucasian Anoxia 402 M 32 Caucasian Anoxia 405 M 32 Caucasian Anoxia 407 M 69 Caucasian Cerebrovascular accident 408 M 32 Caucasian Head trauma 409 F 63 Hispanic Cerebrovascular accident 411 M 55 Caucasian Anoxia 412 M 66 Caucasian Cerebrovascular accident 418 F 62 Hispanic Anoxia 437 M 62 Caucasian Cerebrovascular accident 438 M 56 Caucasian Head trauma 439 F 78 Caucasian Anoxia 448 F 58 Caucasian Anoxia 451 M 58 Caucasian Cerebrovascular accident 453 F 25 Caucasian Anoxia 460 F 43 Hispanic Cerebrovascular accident 461 F 74 Caucasian Cerebrovascular accident 466 M 48 Caucasian Anoxia 474 M 33 Caucasian Anoxia 475 M 27 Caucasian Anoxia 479 M 65 Caucasian Anoxia 484 F 55 Caucasian Cerebrovascular accident 487 M 48 Caucasian Head trauma 488 M 57 Caucasian Head trauma 490 F 60 Caucasian Cerebrovascular accident 496 F 58 Caucasian Cerebrovascular accident 499 F 55 Caucasian Cerebrovascular accident 506 F 48 Caucasian Cerebrovascular accident 515 F 59 Caucasian Cerebrovascular accident 530 F 64 Caucasian Head trauma 532 M 26 Caucasian Head trauma 533 M 28 African American Anoxia 536 F 34 Caucasian Anoxia 542 F 53 Caucasian Cerebrovascular accident 543 F 58 Caucasian Anoxia Page 3 of 7

544 M 45 Caucasian Anoxia 546 F 53 Caucasian Cerebrovascular accident 548 F 61 Caucasian Anoxia 552 M 40 American Indian Head trauma 554 F 43 Caucasian Anoxia 555 M 69 Caucasian Anoxia 556 F 49 Caucasian Cerebrovascular accident 558 M 50 Caucasian Anoxia 561 M 55 African American Cerebrovascular accident 569 M 60 Caucasian Anoxia 572 M 68 Caucasian Cerebrovascular accident 574 M 63 Caucasian Cerebrovascular accident 576 F 55 Caucasian Cerebrovascular accident 577 F 23 Caucasian Cerebrovascular accident 582 F 60 Caucasian Anoxia 589 F 55 Caucasian Cerebrovascular accident 594 F 51 Caucasian Cerebrovascular accident 596 F 17 Caucasian Head trauma 603 F 67 Caucasian Head trauma 605 F 49 Caucasian Cerebrovascular accident 608 F 54 Caucasian Anoxia 611 F 25 Caucasian Cerebrovascular accident 617 F 52 Caucasian Cerebrovascular accident 619 F 45 Caucasian Cerebrovascular accident 625 F 39 Caucasian Anoxia 628 F 62 Caucasian Cerebrovascular accident 634 F 63 Caucasian Cerebrovascular accident 659 F 33 Hispanic Anoxia 686 F 52 Caucasian Anoxia 706 F 53 Caucasian Cerebrovascular accident 715 M 21 Caucasian Head trauma 726 F 48 Caucasian Cerebrovascular accident 728 M 39 Caucasian Cerebrovascular accident 729 F 66 Caucasian Head trauma 736 F 46 Caucasian Anoxia 744 M 57 Caucasian Cerebrovascular accident 750 F 53 Caucasian Anoxia 751 M 29 Caucasian Anoxia 755 F 39 Caucasian Anoxia 758 F 55 Caucasian Cerebrovascular accident 761 M 70 Caucasian Cerebrovascular accident 765 F 39 Caucasian Cerebrovascular accident 766 F 38 Caucasian Anoxia Page 4 of 7

769 M 58 Caucasian Head trauma 772 M 46 Caucasian Anoxia 773 M 46 Caucasian Head trauma 778 M 61 Caucasian Cerebrovascular accident 780 F 48 African American Cerebrovascular accident 788 F 58 Caucasian Cerebrovascular accident 794 M 36 Hispanic Head trauma 807 F 47 Caucasian Cerebrovascular accident 808 M 57 Caucasian Cerebrovascular accident 810 M 37 Caucasian Head trauma 811 M 16 Caucasian Head trauma 812 M 73 Caucasian Cerebrovascular accident 814 F 65 Caucasian Cerebrovascular accident 815 M 52 Caucasian Anoxia 817 F 31 Caucasian Anoxia 818 M 48 Hispanic Cerebrovascular accident 819 F 49 Caucasian Head trauma 820 F 65 Caucasian Cerebrovascular accident 821 F 51 Caucasian Anoxia 839 F 25 African American Cerebrovascular accident 840 M 77 Caucasian Cerebrovascular accident 841 M 74 Caucasian Head trauma 842 F 60 Caucasian Anoxia 847 F 55 Caucasian Cerebrovascular accident 851 F 47 Caucasian Cerebrovascular accident 956 F 68 African American Anoxia 962 M 47 Caucasian Anoxia 966 F 53 Caucasian Head trauma 968 M 54 Caucasian Cerebrovascular accident 970 M 68 Caucasian Anoxia 973 F 63 Caucasian Cerebrovascular accident 974 M 19 Hispanic Anoxia 975 M 46 Hispanic Cerebrovascular accident 976 F 61 Caucasian Head trauma 977 M 54 Caucasian Head trauma 978 F 56 Hispanic Cerebrovascular accident 982 F 30 Caucasian Anoxia 983 M 49 Caucasian Anoxia 985 F 58 Caucasian Cerebrovascular accident 989 F 47 Caucasian Cerebrovascular accident 990 M 38 Caucasian Cerebrovascular accident 994 F 73 Caucasian Cerebrovascular accident 995 F 45 Caucasian Cerebrovascular accident Page 5 of 7

996 F 10 Caucasian Anoxia 997 M 63 Caucasian Anoxia 998 F 63 Caucasian Cerebrovascular accident 999 F 19 Hispanic Anoxia 1001 F 50 American Indian Cerebrovascular accident 1002 M 48 African American Cerebrovascular accident 1003 F 75 Caucasian Cerebrovascular accident 1004 F 45 Caucasian Head trauma 1005 M 45 Caucasian Cerebrovascular accident 1006 M 50 Caucasian Anoxia 1007 M 20 Caucasian Head trauma 1008 M 36 Hispanic Cerebrovascular accident 1009 M 22 Caucasian Cerebrovascular accident 1010 M 63 Caucasian Cerebrovascular accident 1011 M 65 Caucasian Cerebrovascular accident 1012 M 41 Caucasian Anoxia 1013 M 51 Caucasian Cerebrovascular accident 1014 M 55 Caucasian Anoxia 1015 M 59 Caucasian Cerebrovascular accident 1016 M 64 Hispanic Head trauma 1018 M 59 Caucasian Anoxia 1020 F 24 Caucasian Cerebrovascular accident 1022 M 41 Caucasian Anoxia 1024 F 59 Caucasian Anoxia 1025 M 57 Caucasian Cerebrovascular accident 1026 F 55 African American Head trauma 1027 F 63 Caucasian Cerebrovascular accident 1028 F 51 African American Cerebrovascular accident 1030 M 67 Caucasian Cerebrovascular accident 1032 M 64 Caucasian Cerebrovascular accident 1033 F 55 Caucasian Cerebrovascular accident 1042 M 51 Caucasian Cerebrovascular accident 1044 F 19 Caucasian Anoxia 1045 M 48 Caucasian Cerebrovascular accident 1046 M 49 Caucasian Anoxia 1047 M 53 Hispanic Cerebrovascular accident 1051 F 57 African American Cerebrovascular accident 1054 M 19 Caucasian Head trauma 1055 F 29 African American Head trauma 1060 M 49 Hispanic Cerebrovascular accident 1061 M 40 Hispanic Cerebrovascular accident 1063 M 43 Hispanic Head trauma 1066 M 60 Caucasian Cerebrovascular accident Page 6 of 7

1068 M 43 Caucasian Head trauma 1069 M 39 Caucasian Cerebrovascular accident 1074 F 51 African American Cerebrovascular accident 1075 M 56 Caucasian Cerebrovascular accident 1077 F 57 Caucasian Head trauma 1079 M 41 Caucasian Anoxia 1081 M 55 Caucasian Cerebrovascular accident 1084 M 52 Caucasian Cerebrovascular accident 1087 M 51 African American Cerebrovascular accident 1088 F 61 Caucasian Cerebrovascular accident 1089 M 55 Caucasian Anoxia 1090 M 49 Caucasian Cerebrovascular accident 1091 M 74 Caucasian Cerebrovascular accident 1093 F 48 Caucasian Cerebrovascular accident 1094 M 59 African American Cerebrovascular accident 1095 F 60 Caucasian Cerebrovascular accident 1097 M 36 Caucasian Cerebrovascular accident 1098 M 54 Caucasian Head trauma 1101 F 47 Caucasian Anoxia 1102 M 48 Caucasian Cerebrovascular accident 1106 F 20 Caucasian Cerebrovascular accident 1107 F 55 Caucasian Cerebrovascular accident 1108 F 45 African American Cerebrovascular accident 1117 F 66 Caucasian Cerebrovascular accident 1130 F 65 Caucasian Cerebrovascular accident 1155 F 43 Caucasian Cerebrovascular accident 1157 F 59 Hispanic Head trauma Serology information Cytomegalovirus: 124 of 200 donors tested positive and 1 donor was not determined. RPR*: 200 donors tested negative. HIV, HTLV, HbsAg, and HCV**: All donors tested negative. * Rapid Plasma Reagin ** Antibody to Human Immunodeficiency Virus, Antibody to Human T Cell Lymphotropic Virus, Hepatitis B Surface Antigen, Antibody to Hepatitis C Virus, respectively. Page 7 of 7